Evernorth Launches New Benefit Option That Drives Lower Net Cost for Weight Loss Medicines and Limits Patient Cost to No More Than $200 Per Month

Evernorth, a division of The Cigna Group, is launching a new pharmacy benefit offering for weight loss medications WEGOVY® and ZEPBOUND®, capping patient monthly costs at $200 and potentially saving them up to $3,600 annually compared to direct-to-consumer programs; the initiative aims to lower net prescription costs for health plan sponsors while ensuring patient safety through Express Scripts' safety checks and a simplified prior authorization process.

Analysis

Evernorth, The Cigna Group's (NYSE: CI) health services division, has announced a novel pharmacy benefit offering for the popular weight loss medications WEGOVY® and ZEPBOUND®, aiming to significantly improve affordability and access. This initiative caps patient monthly out-of-pocket costs at $200, a figure that also contributes to their annual deductible, potentially saving patients up to $3,600 per year compared to direct-to-consumer programs. The offering, facilitated by direct negotiations with drug manufacturers, is designed to address the growing demand for these FDA-approved treatments by lowering the net cost per prescription for health plan sponsors. Adam Kautzner, President of Evernorth Care Management and Express Scripts, emphasized the program's role in reimagining pharmacy benefits to reduce costs and enhance patient outcomes. Key benefits for patients include not only lower copays and substantial savings but also enhanced safety through Express Scripts' robust checks for adverse drug interactions, simplified and automated prior authorization processes, and a choice of local retail pharmacies or Evernorth's specialized EnGuide Pharmacy for home delivery. For employers and other health plan sponsors, the program promises a significant reduction in the net cost of GLP-1 medications while ensuring patients have access to clinically appropriate options. This strategic move by Evernorth is positioned to meet a critical market need by providing savings, choice, and predictability in the rapidly expanding weight loss drug market, leveraging Express Scripts' capabilities in cost management and patient care.

Key Decisions for Investors

• Investors in The Cigna Group (CI) should view this as a positive strategic development, potentially enhancing Evernorth's market share in pharmacy benefit management by addressing a key cost concern for popular GLP-1 medications, which could drive client acquisition and retention.
• Monitor the adoption rate of this new offering among health plan sponsors and the subsequent impact on Cigna's prescription volumes and revenue within its Evernorth segment, as successful implementation could materially benefit earnings.
• Assess the competitive landscape, as this initiative by Evernorth may pressure other PBMs and insurers to introduce similar cost-containment measures for high-cost specialty drugs, potentially reshaping pricing and benefit structures across the industry.